News and Trends 3 Sep 2019 Gyroscope Targets Age-Related Blindness with €55M Series B UK gene therapy biotech Gyroscope Therapeutics has secured €55.4M in Series B funding to target age-related macular degeneration. Life sciences investor Syncona, which is backed by the UK’s Wellcome Trust, continued its support of the company contributing €52.7M to the round. This brings its total investment in Gyroscope to €90M since the biotech was founded […] September 3, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 20 Aug 2019 Nabriva Therapeutics Gets FDA Green Light for Pneumonia Antibiotic The US FDA has approved Nabriva Therapeutics’ Xenleta for treating community-acquired bacterial pneumonia, the first in a new class of antibiotics developed to treat this condition. Xenleta, also known as lefamulin, was discovered almost 10 years ago by Nabriva Therapeutics, a spinout company from Novartis split between Austria, Ireland and the US. The approval is […] August 20, 2019 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Expert Advice 7 Aug 2019 Why Making the Jump from Pharma to Biotech Can be a Life Changing Experience In less than two years, Orchard Therapeutics has changed from a small, relatively unknown UK biotech specializing in gene therapy into a billion euro company listed on the Nasdaq. This is in no small part due to the skills and experience of Mark Rothera, its CEO and President, who joined the company in 2017. Orchard […] August 7, 2019 - 13 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 30 Jul 2019 The First Approved NASH Therapy? Genfit is poised to become the first company to get a treatment for NASH to market — something that could happen as early as 2020, should its late 2019 phase III trial results be positive. I spoke to Dean Hum, the current COO and CSO of Genfit, to find out more about the company’s 20-year […] July 30, 2019 - 6 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
More News! 27 Jun 2019 German Biotech Will Target Parkinsonian Disorders with €12M Series A Modag has developed a candidate drug targeting the neurodegenerative disease multiple system atrophy, which it plans to take to the clinic with €12M in Series A funds. Multiple system atrophy is a rare disorder, with similar symptoms to Parkinson’s disease, that is caused by breakdown of neurons in parts of the brain. The German biotech’s […] June 27, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Expert Advice 8 Jun 2019 Why Sticking to Your Beliefs is Important for Biotech Success Galapagos is an undeniable success story. Set up in 1999, it is now one of the largest and most successful biotechs in Europe. A key driving force behind the company is Onno van de Stolpe, its founder and CEO. After doing an internship at Biogen while at university, van de Stolpe knew he wanted to […] June 8, 2019 - 11 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 23 May 2019 Why Clinical Trial Design Can Make or Break Your Company Andreas Wallnöfer spent over 20 years working on drug development at Roche before moving to BioMedPartners to apply his expertise to biotech investment. At our recent Labiotech Refresh event in Zurich, he explained why good clinical trial design can be key to a biotech’s success. Wallnöfer was one of the pioneers of ‘proof of concept’ […] May 23, 2019 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2019 UK Immune Cell Therapy Biotech Founded with €40M Series A Quell Therapeutics, a London-based biotech developing immune cell therapies to target transplant rejection and autoimmune and inflammatory diseases, launched today with €40M series A funding. UK life sciences trust Syncona is the lead investor, with a €38.8M stake in the company. Syncona will own a controlling 69% of the business, reflecting their large initial investment. […] May 20, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2019 Update: British RNA Biotech Increases Series A to €34M Update (20/05/19): Storm Therapeutics has increased its series A financing round by an additional €16M (£14M) to €34M (£30M), which the company plans to use to advance its pipeline of RNA focused drug candidates towards the clinic. Seroba Life Sciences, an Irish VC focusing on new and innovative therapies, is the key new investor. Existing […] May 20, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 13 May 2019 Putting DNA Repair on the Map Niall Martin is on a mission to put DNA repair on the map. He has already gone pretty far along the way to doing this, as the leader of the team that developed the blockbuster cancer drug Lynparza. He is now seeking to repeat this early success at Artios, where he is CEO. Martin talked […] May 13, 2019 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Expert Advice 8 May 2019 Why It’s Important to “Think Big” When Raising Money for Your Company There are not many people who can say they led one of Europe’s largest biotechs and launched the first approved gene therapy in Europe. Joern Aldag, now CEO at Austrian biotech Hookipa Pharma, has done both. Aldag got into biotech because he wanted to use his entrepreneurial skills to advance medicine. After 9 years of […] May 8, 2019 - 9 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 1 May 2019 UK Genome Diagnostics Biotech Closes €27M Series B to Support NHS Cambridge-based Congenica has closed a €27M (£23.3M) series B fundraising round to support the use of its rare disease diagnostics platform by the newly formed NHS Genomic Medicine Service, as well as to allow the company to expand internationally. The genomics diagnostic company received a €15.5M (£13.3M) investment, led by the London-based fund management firm […] May 1, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email